Apimeds - נכסים נקיים למניה בודדת APUS

Apimeds Pharmaceuticals (APUS) is developing breakthrough neuropathies treatments utilizing the molecular biology of bee toxins. This historical book value chart for the stock on GURU.Markets contains data where the indicator remains at 69.94. Development is based on unique raw materials and clinical trials in the US, while growing demand for natural bioccomponents ensures stable sales for the company.

This indicator reflects the residual value of net assets per share, defined as the difference between the company's total assets and liabilities. For Apimeds Pharmaceuticals (APUS), whose neurology developments are protected by Western standards and isolated from geopolitical risks, the steady trend in the book value per share confirms effective capital management amid low sanctions pressure.